Ascendis Pharma A/S
Market Cap
$14.08B
P/E Ratio
-52.13
EPS
$-4.40
Dividend Yield
0.00%
52-Week Range
$150.89 — $250.74
Volume
569.45K
Avg Volume
719.69K
Beta
0.48
Get alerted when ASND hits your target price.
Free — enter your email to get started
P/E (TTM)
-52.13
Forward P/E
54.51
PEG Ratio
-0.85
P/S (TTM)
16.13
P/B (TTM)
-71.14
P/FCF
4919.38
EV/EBITDA
-198.78x
EV/Sales
—
ROE (TTM)
1.28%
ROA (TTM)
-0.17%
ROIC
0.07%
Gross Margin
0.86%
Operating Margin
-0.19%
Net Margin
-0.29%
Debt/Equity
-5.35
Current Ratio
1.04
EPS Growth (YoY)
+0.41%
Revenue Growth (YoY)
+2.55%
EPS Growth (3Y)
+0.29%
EPS Growth (5Y)
+0.11%
Sales Growth (3Y)
+1.83%
Sales Growth (5Y)
+2.24%
EPS Est (This Year)
$4.21
EPS Est (Next Year)
$10.25
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$10.03
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $287.17(25.2% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
61.38M
Float
60.88M
Free Float %
99.18%
Sector
Healthcare
Industry
Biotechnology
Country
DK
Exchange
NASDAQ
IPO Date
2015-01-28
Employees
1017
CEO
Jan Moller Mikkelsen
Index Membership
—
Website
https://ascendispharma.com
Ascendis Pharma A/S (ASND) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $14.08B, a P/E ratio of -52.13, ASND is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare ASND against other stocks using dozens of fundamental and technical filters.
Ascendis Pharma A/S (ASND) has a trailing twelve-month (TTM) P/E ratio of -52.13. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Ascendis Pharma A/S (ASND) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Ascendis Pharma A/S (ASND) has a market capitalization of $14.08 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Ascendis Pharma A/S (ASND) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $287.17 implies 25.2% upside from the current price.